MedKoo Biosciences, Inc.
Tel:   +1-919-636-5577    Fax:   +1-919-980-4831    Email:   sales@medkoo.com
Search
Login Register
Search
MedKoo Cat#: 571536 | Name: Framycetin

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Framycetin is a component of neomycin that is produced by Streptomyces fradiae. It can enhance effectiveness of topical antibacterial treatment of adenoiditis. It is also used in burn therapy.

Chemical Structure

Framycetin
Framycetin
CAS#119-04-0 (free base)

Theoretical Analysis

MedKoo Cat#: 571536

Name: Framycetin

CAS#: 119-04-0 (free base)

Chemical Formula: C23H46N6O13

Exact Mass: 614.3123

Molecular Weight: 614.65

Elemental Analysis: C, 44.94; H, 7.54; N, 13.67; O, 33.84

Price and Availability

This product is currently not in stock but may be available through custom synthesis. To ensure cost efficiency, the minimum order quantity is 1 gram. The estimated lead time is 2 to 4 months, with pricing dependent on the complexity of the synthesis (typically high for intricate chemistries). Quotes for quantities below 1 gram will not be provided. To request a quote, please click the button below. Note: If this product becomes available in stock in the future, pricing will be listed accordingly.
Bulk Inquiry
Related CAS #
55298-68-5 (palmitate) 1406-04-8 (undecylenate) 119-04-0 (free base) 1405-10-3 (sulfate) 4146-30-9 (B sulfate)
Synonym
Framycetin; Fradiomycin; Actilin; Soframycin; Neomycin B; Fradiomycin B
IUPAC/Chemical Name
(2S,3S,4R,5R,6R)-5-amino-2-(aminomethyl)-6-(((2R,3S,4R,5S)-5-(((1R,2R,3S,5R,6S)-3,5-diamino-2-(((2R,3R,4R,5S,6R)-3-amino-6-(aminomethyl)-4,5-dihydroxytetrahydro-2H-pyran-2-yl)oxy)-6-hydroxycyclohexyl)oxy)-4-hydroxy-2-(hydroxymethyl)tetrahydrofuran-3-yl)oxy)tetrahydro-2H-pyran-3,4-diol
InChi Key
PGBHMTALBVVCIT-VCIWKGPPSA-N
InChi Code
InChI=1S/C23H46N6O13/c24-2-7-13(32)15(34)10(28)21(37-7)40-18-6(27)1-5(26)12(31)20(18)42-23-17(36)19(9(4-30)39-23)41-22-11(29)16(35)14(33)8(3-25)38-22/h5-23,30-36H,1-4,24-29H2/t5-,6+,7-,8+,9-,10-,11-,12+,13-,14-,15-,16-,17-,18-,19-,20-,21-,22-,23+/m1/s1
SMILES Code
N[C@@H]1[C@@H](O[C@@H]2[C@H](N)[C@@H](O)[C@H](O)[C@@H](CN)O2)[C@H](O[C@H]3[C@H](O)[C@H](O[C@@H]4[C@H](N)[C@@H](O)[C@H](O)[C@H](CN)O4)[C@@H](CO)O3)[C@@H](O)[C@H](N)C1
Appearance
Solid powder
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
Soluble in DMSO
Shelf Life
>2 years if stored properly
Drug Formulation
This drug may be formulated in DMSO
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
More Info

Preparing Stock Solutions

The following data is based on the product molecular weight 614.65 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
1: Wu Z, Yaqoob I, Afzal M, Iqbal FM, Hassan W, Chen X. Evaluation and characterization of framycetin sulphate loaded hydrogel dressing for enhanced wound healing. PLoS One. 2025 Apr 17;20(4):e0317273. doi: 10.1371/journal.pone.0317273. PMID: 40244999; PMCID: PMC12005552. 2: Drugea RI, Siteavu MI, Pitoiu E, Delcaru C, Sârbu EM, Postolache C, Bărăităreanu S. Prevalence and Antibiotic Resistance of Escherichia coli Isolated from Raw Cow's Milk. Microorganisms. 2025 Jan 19;13(1):209. doi: 10.3390/microorganisms13010209. PMID: 39858977; PMCID: PMC11767543. 3: Wijesekera A, Chiam Xu Wen A, Walker A, Anders C. Effects of seasonal, geographical and demographic factors on otitis externa microbiota in Queensland, Australia. Aust J Gen Pract. 2024 Nov-Supplement;53(11 Suppl):S27-S32. doi: 10.31128/AJGP-02-24-7152. PMID: 39542671. 4: Revillo Imbernon J, Weibel JM, Ennifar E, Prévost G, Kellenberger E. Structural analysis of neomycin B and kanamycin A binding Aminoglycosides Modifying Enzymes (AME) and bacterial ribosomal RNA. Mol Inform. 2024 Jul;43(7):e202300339. doi: 10.1002/minf.202300339. Epub 2024 Jun 10. PMID: 38853661. 5: Heel SV, Breuker K. Investigating the Intramolecular Competition of Different RNA Binding Motifs for Neomycin B by Native Top-Down Mass Spectrometry. Chempluschem. 2024 Aug;89(8):e202400178. doi: 10.1002/cplu.202400178. Epub 2024 May 17. PMID: 38758051. 6: Gore DD, Sharma N, Mishra N, Parmar PK, Ranjana S, Kumar D, Jachak SM, Jena G, Tikoo K, Bansal AK, Singh IP. Wound-healing effect of topical nanoemulsion- loaded cream and gel formulations of Hippophae rhamnoides L. (sea buckthorn) fruit oil and their acute dermal toxicity study on female SD rats. Indian J Pharmacol. 2024 Mar 1;56(2):120-128. doi: 10.4103/ijp.ijp_370_23. Epub 2024 Apr 30. PMID: 38687316; PMCID: PMC11160998. 7: Heel SV, Juen F, Bartosik K, Micura R, Kreutz C, Breuker K. Resolving the intricate binding of neomycin B to multiple binding motifs of a neomycin-sensing riboswitch aptamer by native top-down mass spectrometry and NMR spectroscopy. Nucleic Acids Res. 2024 May 8;52(8):4691-4701. doi: 10.1093/nar/gkae224. PMID: 38567725; PMCID: PMC11077050. 8: Amanah NK, Mashudi S, Munawaroh S, Azzarin AW, Karimah FN, Gunawan F. Exploring the Efficacy of Musa Cavendish Stem Extract (Mucase) as a Novel Wound Dressing: A Comparative Study With Sofratulle®. Cureus. 2024 Feb 18;16(2):e54411. doi: 10.7759/cureus.54411. PMID: 38505455; PMCID: PMC10950323. 9: Valan AS, Kolli S, Eswaramoorthy R, Krithikadatta J, Malli Sureshbabu N. Comparison of Antibacterial Efficacy of Triple Antibiotic-Loaded Hydrogel Versus Modified Triple Antibiotic-Loaded Hydrogel as Intracanal Medicament Against Enterococcus faecalis: An In vitro Study. Eur Endod J. 2024 Mar;9(2):154-160. doi: 10.14744/eej.2023.06977. PMID: 38456465; PMCID: PMC10938355. 10: Singh D, Sharma R, Jamal S, Agarwal M, Grover S, Batra JK. Identification and characterization of repurposed small molecule inhibitors of Mycobacterium tuberculosis caseinolytic protease B (ClpB) as anti-mycobacterials. Int J Biol Macromol. 2024 Apr;264(Pt 1):130614. doi: 10.1016/j.ijbiomac.2024.130614. Epub 2024 Mar 4. PMID: 38447849. 11: Peracchia C. Nerve Structure-Function: Unusual Structural Details and Unmasking of Sulfhydryl Groups by Electrical Stimulation or Asphyxia in Axon Membranes and Gap Junctions. Int J Mol Sci. 2023 Sep 1;24(17):13565. doi: 10.3390/ijms241713565. PMID: 37686371; PMCID: PMC10488147. 12: Kumar S, Singh H, Prajapat M, Sarma P, Bhattacharyya A, Kaur H, Kaur G, Shekhar N, Kaushal K, Kumari K, Bansal S, Mahendiratta S, Chauhan A, Singh A, Soloman Singh R, Sharma S, Thota P, Avti P, Prakash A, Kuhad A, Medhi B. Structural-Based Virtual Screening of FDA-Approved Drugs Repository for NSP16 Inhibitors, Essential for SARS-COV-2 Invasion Into Host Cells: Elucidation From MM/PBSA Calculation. Bioinform Biol Insights. 2023 Jul 31;17:11779322231171777. doi: 10.1177/11779322231171777. PMID: 37533429; PMCID: PMC10392196. 13: Heel SV, Bartosik K, Juen F, Kreutz C, Micura R, Breuker K. Native Top-Down Mass Spectrometry Uncovers Two Distinct Binding Motifs of a Functional Neomycin- Sensing Riboswitch Aptamer. J Am Chem Soc. 2023 Jul 19;145(28):15284-15294. doi: 10.1021/jacs.3c02774. Epub 2023 Jul 7. PMID: 37420313; PMCID: PMC10360057. 14: Karina K, Rahmania D, Andrew H, Ekaputri K, Biben JA, Martina NR. Wound healing in stage IV pressure injury with use of adjunct autologous activated platelet-rich plasma therapy: a case report. Wounds. 2023 Jan;35(1):E14-E16. doi: 10.25270/wnds/22002. PMID: 36749992. 15: Alinda MD, Christopher PM, Listiawan MY, Endaryanto A, Suroto H, Rantam FA, Hendradi E, Notobroto HB, Prakoeswa CRS. The efficacy of topical adipose mesenchymal stem cell-conditioned medium versus framycetin gauze dressing in chronic plantar ulcer of leprosy: A randomized controlled trial. Indian J Dermatol Venereol Leprol. 2023 Sep-Oct;89(5):656-664. doi: 10.25259/IJDVL_784_2021. PMID: 36688887. 16: la Encina AC, Martínez-Rodríguez N, Ortega-Aranegui R, Cortes-Bretón Brinkmann J, Martínez-González JM, Barona-Dorado C. Anatomical variations and accessory structures in the maxilla in relation to implantological procedures: an observational retrospective study of 212 cases using cone-bean computed tomography. Int J Implant Dent. 2022 Nov 28;8(1):59. doi: 10.1186/s40729-022-00459-7. PMID: 36441355; PMCID: PMC9705638. 17: Palasser M, Breuker K. RNA Chemical Labeling with Site-Specific, Relative Quantification by Mass Spectrometry for the Structural Study of a Neomycin- Sensing Riboswitch Aptamer Domain. Chempluschem. 2022 Nov;87(11):e202200256. doi: 10.1002/cplu.202200256. Epub 2022 Oct 11. PMID: 36220343; PMCID: PMC9828840. 18: Smittiset B, Banomyong D, Ruangsawasdi N, Kaewprag J. In vitro bactericidal efficacy of a new triple antibiotic paste formulation against Enterococcus faecalis biofilm. Aust Endod J. 2023 Sep;49 Suppl 1:9-17. doi: 10.1111/aej.12683. Epub 2022 Sep 8. PMID: 36073834. 19: da Silva Magalhães K, Kuerten Gil AC, Goulart TS, Schuldt DPV, Coelho BS, Figueiredo DR, Garcia LDFR, de Almeida J. Efficacy of disinfection procedures performed prior to regenerative endodontic therapy: An integrative review. Aust Endod J. 2023 Aug;49(2):418-427. doi: 10.1111/aej.12670. Epub 2022 Aug 6. PMID: 35932453. 20: Mei JA, Johnson W, Kinn B, Laskey E, Nolin L, Bhamare P, Stalker C, Dunman PM, Wozniak RAF. Antimicrobial Activity of a Triple Antibiotic Combination Toward Ocular Pseudomonas aeruginosa Clinical Isolates. Transl Vis Sci Technol. 2022 May 2;11(5):26. doi: 10.1167/tvst.11.5.26. PMID: 35612831; PMCID: PMC9145016.